Skip to content

About the difference in efficacy depending on the carbon number of medium-chain fatty acids

The difference in efficacy of octanoic acid and decanoic acid, medium-chain fatty acids. - The difference in efficacy of octanoic acid and decanoic acid, medium-chain fatty acids.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000051444
Enrollment
60
Registered
2023-06-27
Start date
2023-06-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frail elderly subjects

Interventions

octanoate group&quot
that takes MCT (C8:0). C8:0 Mix 6 g (54 kcal) of MCT containing about 97% with rice or miso soup and take it for lunch. The intervention will last approximately 1.5 months. The second group is the &qu
decanoic acid group&quot
taking MCT (C10:0). C10:0 Mix 6 g (54 kcal) of MCT containing about 97% with rice or miso soup and take it for lunch. The intervention will last approximately 1.5 months. The third group is the &quot
LCT group,&quot
that takes LCT. LCT is mixed with rice or miso soup and consumed for lunch. The intervention will last approximately 1.5 months.

Sponsors

Tezukayama University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Elderly subjects in a nursing care home for the elderly volunteered to participate in a 3-mo dietary supplement intervention program. All residents in this nursing care home need special care by other people for living. They are classified into Japanese nursing care levels with number between 1 and 5 based on assessed care needs.

Exclusion criteria

Exclusion criteria: Those in need of enteral or intravenous nutritional therapy. Patients who have severe dysphagia and cannot take food orally. Those who have a level of consciousness rating (JCS: Japan coma scale) of 2-2 or higher. Type I diabetes mellitus and those with serious cardiac, hepatic, renal, or hematological diseases. Fasting blood glucose level of 200 mg/dl or higher. CRP 2.0 mg/dl or higher. Persons who frequently fall ill. BMI 25.0 kg/m2 or higher. Subjects with relevant food allergies. Persons who are unable to understand the study. Persons who are judged not to be included in the study by the facility director, who is the facility physician.

Design outcomes

Primary

MeasureTime frame
Changes in physical function, cognitive function, and swallowing function will be compared before and after 1.5 months of intervention. Body measurements and body composition will be estimated by body weight, body mass index (BMI), body fat percentage, body fat mass, skeletal muscle mass, upper arm circumference (AC), triceps subcutaneous fat thickness (TSF), upper arm muscle circumference (AMC), upper arm muscle area (AMA), and lower leg circumference (CC). Physical performance is estimated by grip strength, maximum walking speed, number of repetitive openings and closings of the lower extremities, quadriceps endurance, lower extremity muscle strength, respiratory muscle function (peak flow meter), and functional independence measures (FIM). Cognitive function is estimated with the Mini-Mental State Examination (MMSE) and the N Mental State Rating Scale for the Elderly (NM scale). Eating and swallowing function is estimated with the Repeated Saliva Swallowing Test (RSST), the Revised Water Swallowing Test (MWST), and tongue pressure muscle strength.

Countries

Japan

Contacts

Public ContactSakiko Abe

Tezukayama University Department of Food and Nutrition, Faculty of Contemporary Human Life Science

sa-abe@tezukayama-u.ac.jp0742-41-4742

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026